Did you know? You can suggest edits to improve this peptide information.
Overview
What is Cardiogen?
Cardiogen (Ala-Glu-Asp-Arg / AEDR) is a synthetic tetrapeptide bioregulator developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It targets cardiac tissue through modulation of fibroblast proliferation, suppression of cardiomyocyte apoptosis via p53 downregulation, and upregulation of cytoskeletal and nuclear matrix proteins. Preclinical research has explored its potential in cardiac remodeling, myocardial injury recovery, and age-related cardiovascular decline. All published studies to date are based on in vitro experiments and animal models.
Key Benefits
Direct systemic delivery for cardiac tissue support, established reconstitution protocols, most commonly studied administration route in preclinical research
Mechanism of Action
Subcutaneous injection provides systemic distribution allowing AEDR tetrapeptide to reach cardiac tissue and modulate fibroblast proliferation and cardiomyocyte apoptosis pathways
Molecular Information
Weight
489.47 Da
Length
4 amino acids
Type
Tetrapeptide
Amino Acid Sequence:
Ala-Glu-Asp-Arg (AEDR)
* Synthetic bioregulatory peptide (H-Ala-Glu-Asp-Arg-OH), molecular formula C₁₈H₃₁N₇O₉
Research Indications
Cardiac Tissue Support
Preclinical models suggest cardiomyocyte proliferation stimulation and apoptosis suppression through p53 downregulation
Post-Injury Remodeling
Coronary artery ligation mouse models suggest reduced necrotic zones and improved survival outcomes
Age-Related Decline
Stimulates cardiac cell proliferation in both young and aged tissue cultures, potentially addressing age-related cardiovascular deterioration
Research Protocols
Disclaimer
Injectable dosing protocols are community-derived. No human clinical trials have established optimal dosing for Cardiogen. All preclinical studies used in vitro concentrations (ng/ml range), not injectable human doses. This is not medical advice. Consult a healthcare provider before use.
Timing
Morning subcutaneous injection. Rotate injection sites between abdomen, thigh, and upper arm.
Peptide Interactions
How to Reconstitute
Important
Always use bacteriostatic water (BAC). Sterile technique is essential.
Allow vial to reach room temperature (15-20 minutes)
Clean vial top with alcohol swab and allow to dry
Calculate required bacteriostatic water volume using the calculator below
Draw calculated volume of bacteriostatic water into syringe
Inject water slowly down the inside wall of the vial (never directly onto powder)
Gently swirl until powder completely dissolves (never shake)
Solution should be clear - discard if cloudy or contains particles
Store reconstituted solution in refrigerator at 2-8°C, protected from light
Quality Indicators
White Lyophilized Powder
Pure Cardiogen appears as white to off-white lyophilized powder or cake
Clear Reconstituted Solution
Properly reconstituted solution should be crystal clear with no particles or cloudiness
Certificate of Analysis
Should include HPLC purity verification (>97%), sequence confirmation (AEDR), and mass spectrometry data
Research Use Only
Cardiogen is not approved for human use - ensure proper research context and documentation
Discolored or Cloudy Solution
Yellow, brown, or cloudy reconstituted solution indicates degradation - do not use
What to Expect
- Week 1-2: No significant observable changes expected
- Week 2-4: Preclinical research suggests cellular-level effects on cardiac tissue
- Long-term: Benefits are theoretical based on animal and in vitro data only
- Side effects: Minimal injection site reactions reported
- No human clinical trials have established efficacy timelines
Side Effects & Safety
- Not approved for human use by any regulatory agency
- All published research is preclinical (animal and in vitro studies)
- Use sterile injection technique and rotate injection sites
- Store reconstituted peptide in refrigerator, protected from light
- Not recommended during active cancer due to proliferative effects on fibroblasts
- Contraindicated in pregnancy and lactation due to absence of safety data
- Medical supervision recommended
References
Cytoskeletal and Nuclear Matrix Protein Expression (2012)
Tetrapeptide H-Ala-Glu-Asp-Arg-OH enhanced expression of cytoskeletal proteins (actin, tubulin, vimentin) by 2-5 times and nuclear matrix proteins (lamin A, lamin C) by 2-3 times in cultured mouse embryonic fibroblasts, establishing the mechanism for its cardioprotective activity.
View Study (opens in new tab) →Myocardial Tissue Culture in Young and Old Rats (2009)
Cardiogen demonstrated significant stimulating effect on cell proliferation in myocardial tissue from both young and old rats. Immunohistochemical analysis showed decreased p53 protein expression, indicating inhibition of apoptosis in cardiac tissue.
View Study (opens in new tab) →Tumor-Modifying Effect on M-1 Sarcoma (2009)
Dose-dependent inhibition of M-1 sarcoma growth through hemorrhagic necrosis and stimulation of tumor cell apoptosis. Mechanism operated through disruption of tumor vascular network rather than direct cytostatic effects.
View Study (opens in new tab) →Quick Start Guide
Community Poll
Question 1 of 10
What is your experience with this compound?
Poll Results
Loading results...
Community Insights
Self-reported by PepPedia users. Not clinical evidence. Health changes reflect all users, including those taking multiple compounds.
Was this helpful?
Your feedback helps us improve PepPedia